Altay Therapeutics Closes $37 Million Series A Financing to Advance First Oral DUX4 Inhibitor for FSHD into the Clinic
For best results when printing this announcement, please click on link below: Altay Therapeutics Closes $37 Million Series A Financing to Advance First Oral DUX4 Inhibitor for FSHD into the Clinic DX5057 is an orally administered small molecule designed to inhibit DUX4 transcriptional activity and expression of its tar